TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04294368

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medica Nutrition SolCarb (Targeted Fortification)
Description: Participants in the experimental group will receive a dose that will vary depending on the base carbohydrate content in the donor breast milk for each particular batch of donor breast milk

Intervention type: OTHER
Group type: OTHER
Intervention: Analysis with Miris (AB) Human Milk Analyzer
Description: For participants in both the control and the experimental arms, each batch of donor milk will be analyzed using the Miris Human Milk Analyzer. Manufacturer recommendations for milk analysis will be strictly followed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis with Miris (AB) Human Milk Analyzer
Description: For participants in both the control and the experimental arms, each batch of donor milk will be analyzed using the Miris Human Milk Analyzer. Manufacturer recommendations for milk analysis will be strictly followed.
Study: NCT01560390

Intervention type: DRUG
Group type: OTHER
Intervention: Rémifentamil + KETAMINE
Description: All consecutive mechanically ventilated patients admitted in the ICU will be randomized to receive an infusion of 0.15 mg/kg/h of kétamine or placebo. Nurses and physicians will be blinded of the allocation arm. The infusion of ketamine will be stopped as soon as remifentanil will be discontinued by the physician.

Intervention type: DRUG
Group type: OTHER
Intervention: Rémifentamil + KETAMINE
Description: All consecutive mechanically ventilated patients admitted in the ICU will be randomized to receive an infusion of 0.15 mg/kg/h of kétamine or placebo. Nurses and physicians will be blinded of the allocation arm. The infusion of ketamine will be stopped as soon as remifentanil will be discontinued by the physician.

Intervention type: DRUG
Group type: OTHER
Intervention: ketamine
Description: to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.

Intervention type: DRUG
Group type: OTHER
Intervention: ketamine
Description: to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
Study: NCT00629187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Before taking part in this study, subjects will have stem cells collected in a procedure called apheresis. Once on this study, subjects will be admitted to the hospital and receive daily doses of temozolomide by mouth for 5 days. Stem cells will be given back to subjects who will remain in the hospital until blood counts have recovered. Doses of temozolomide will range from 350 mg to 1500 mg/m(squared) daily for 5 days (total dose 1750 to 7500 mg/m(squared).
Study: NCT02552524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS active then rTMS placebo
Description: A 20 minute session of rTMS active at the frequency of 10 Hz then, 7 days later, a 20 minute session of rTMS placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS placebo then rTMS active
Description: A 20 minute session of rTMS placebo then, 7 days later, a 20 minute session of rTMS at the frequency of 10 Hz
Study: NCT01884376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromaix
Study: NCT00829517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer-assisted provision of hormonal contraception
Description: a computer program available at a kiosk will offer women information about and a prescription for hormonal contraception that they can ask their clinician to sign.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STI module
Description: computer module available at a kiosk that will encourage women to be screened for chlamydia
Study: NCT00848640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg twice daily
Study: NCT00702234

Intervention type: BIOLOGICAL
Intervention: Corifollitropin alfa
Description: Subcutaneous (SC) administration of corifollitropin alfa at a dose of 150 μg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.

Intervention type: BIOLOGICAL
Intervention: GnRH antagonist
Description: SC administration of a GnRH antagonist at a dose of 0.25 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.

Intervention type: BIOLOGICAL
Intervention: (rec)hCG
Description: SC administration of (rec)hCG at a dose of 5,000-10,000 IU/250 µg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
Study: NCT02635633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous thetaburst stimulation
Description: On 4 consecutive days patients receive 5 cTBS trains with a 10min intertrain-interval. One cTBS train consists of 600 pulses delivered in bursts at theta frequency (200ms) during 40s. Each burst comprises 3 pulses at 50Hz. Focal stimulation occurs over the epileptogenic focus (EF), perpendicular to the local gyral geometry, using online neuronavigation. Stimulation intensity is set relative to the resting motor threshold (rMT) determined at baseline (80% rMT). Stimulation intensity is further adjusted to the coil-cortex distance at the EF with the following formula: adjusted MT% (AdjMT) = rMT + 2,7\*(DEF-DM1) \[DEF = distance over EF; DM1 = distance over M1\]. If rMT exceeds the capacity of the stimulator output, stimulation intensity is 100% of maximal stimulator output (MSO).
Study: NCT00702234

Intervention type: BIOLOGICAL
Intervention: FSH
Description: SC administration of FSH at a dose not to exceed 225 IU/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.

Intervention type: DRUG
Intervention: Progesterone
Description: Vaginal administration of progesterone at a dose of at least 600 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
Study: NCT01540877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of capsaicin 0.6%
Description: topical application of 0.6% capsaicin on the volar forearm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of local anesthetics (EMLA plaster)
Description: topical application of EMLA on the volar forearm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of 1 capsaicin 0.6% and 2. EMLA
Description: topical application of 1. 0.6% capsaicin and 2. EMLA on the volar forearm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of 1. EMLA and 2. capsaicin 0.6%
Description: topical application of 1. EMLA and 2. 0.6% capsaicin on the volar forearm
Study: NCT03899285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram 20mg or 40 mg (phase 2)
Description: For non-responders, a randomisation 1:1 was chosen. The group A will receive 40 mg and the group B will receive 20 mg once daily of citalopram for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Citalopram 20mg or 40 mg (phase 2)
Description: For non-responders, a randomisation 1:1 was chosen. The group A will receive 40 mg and the group B will receive 20 mg once daily of citalopram for 14 days.
Study: NCT03435510

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Live Donor Champion Program
Description: Even with adequate education of live donation, many KT candidates still feel ill equipped to ask others to consider donating. Friends and family are often eager to help and may not be able to serve as donors themselves, but might be able to provide substantial instrumental support. An LDC is a friend or family member who serves as an advocate for the candidate in their pursuit of live donation. The Johns Hopkins Comprehensive Transplant Center has developed a 6-month program that provides education and advocacy training to waitlist candidates and their LDCs. The instrumental support provided by the LDC bridges a critical link between education and action.Using LDCs to increase live donation is a novel approach that has garnered widespread enthusiasm.
Study: NCT01637337

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic pyelolithotomy
Description: laparoscopy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: percutaneous nephrolithotomy
Description: percutaneous nephrolithotomy
Study: NCT02672631

Intervention type: OTHER
Intervention: physical examination
Description: Investigators will apply for evaluate clinical median nerve function to all of groups. (Adductor pollicis power (x/5), sense exam(normal/hipoestesia/anestesia) of hand, tinnel test(+/-), DASH score, DN4 neuropathic pain score)

Intervention type: OTHER
Intervention: physical examination
Description: Investigators will apply for evaluate clinical median nerve function to all of groups. (Adductor pollicis power (x/5), sense exam(normal/hipoestesia/anestesia) of hand, tinnel test(+/-), DASH score, DN4 neuropathic pain score)

Intervention type: OTHER
Intervention: DTI
Description: Investigators will apply for evaluate median nerve healing countable results to all of groups (apparent diffusion coefficient for avarage diffusion (ADC) and fractional anisotropy diffusion orientation(FA) - FA :0 means diffusion is homogenic FA:1 means tissue has heterogenic diffusion

Intervention type: OTHER
Intervention: DTI
Description: Investigators will apply for evaluate median nerve healing countable results to all of groups (apparent diffusion coefficient for avarage diffusion (ADC) and fractional anisotropy diffusion orientation(FA) - FA :0 means diffusion is homogenic FA:1 means tissue has heterogenic diffusion

Intervention type: OTHER
Intervention: ENMG
Description: Investigators will apply for evaluate median nerve healing countable results to all of groups. And they will evaluate motor nerve transmission speed, sensitive nerve transmission speed and united muscle action potential

Intervention type: OTHER
Intervention: ENMG
Description: Investigators will apply for evaluate median nerve healing countable results to all of groups. And they will evaluate motor nerve transmission speed, sensitive nerve transmission speed and united muscle action potential
Study: NCT03771534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen gas
Description: Brief maternal administration of 65-70% O2 via a face mask during the last trimester
Study: NCT01810926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Fludarabine
Description: iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Thiotepa
Description: iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals
Study: NCT01314014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imexon
Description: Amplimexon will be administered daily on Days 1-5 of 21-day treatment cycles as an intravenous infusion over a time course of 60 minutes. Subjects will receive 17 cycles of therapy for a total of one year on treatment. The Amplimexon starting dose for each subject in this study is 1000 mg/m² on each treatment day. Dose may be reduced by 25% for toxicity; after 2 dose reductions, subjects must be withdrawn from treatment.
Study: NCT03500835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App
Description: 1. 6 month app intervention: Problem Food Withdrawal, Snacking Elimination and Food Amount Reduction~2. Daily Weigh In~3. App based reminders~4. Follow Up: Face-to-face clinic visits at 3,6,12 and 18 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App
Description: 1. 6 month app intervention: Problem Food Withdrawal, Snacking Elimination and Food Amount Reduction~2. Daily Weigh In~3. App based reminders~4. Follow Up: Face-to-face clinic visits at 3,6,12 and 18 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: 1. 6 month addiction based intervention: Problem Food Withdrawal, Snacking Elimination and Food Amount Reduction.~2. Daily Weighing~3. Daily Text messages from Coach~4. Weekly 15 minute phone meetings with Coach~5. Follow Up: Face-to-face clinic visits at 3,6,12 and 18 months post consent

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic: Modified KidsNFitness
Description: 1. 6 month in-clinic, evidence-based, multi-disciplinary intervention~2. 90 minute sessions, in clinic that occur every month for 6 months~3. Follow Up: Face-to-face clinic visits Monthly x 6 months followed by face-to-face visit at12 and 18 months.
Study: NCT01159756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travacom
Description: Travacom ophthalmic solution (1 drop per day)
Study: NCT02852486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 Mg Oral Tablet
Description: 30 mg/day, orally, for 3 months, before imatinib discontinuation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: imatinib discontinuation
Description: imatinib discontinuation after 3 months of pioglitazone
Study: NCT01482819

Intervention type: DEVICE
Group type: OTHER
Intervention: galyfilcon A
Description: contact lenses worn bilaterally for 8-12 hours

Intervention type: DEVICE
Group type: OTHER
Intervention: galyfilcon A
Description: contact lenses worn bilaterally for 8-12 hours
Study: NCT02980159

Intervention type: OTHER
Intervention: Triage liaison physician
Description: A triage liaison physician is present from 7:30 am to 10:30 pm, Monday to Friday, with the mission to evaluate quickly patients who cannot be immediately installed in an ED room
Study: NCT01482819

Intervention type: DEVICE
Group type: OTHER
Intervention: galyfilcon A
Description: contact lenses worn bilaterally for 8-12 hours

Intervention type: DEVICE
Group type: OTHER
Intervention: galyfilcon A
Description: contact lenses worn bilaterally for 8-12 hours

Intervention type: DEVICE
Group type: OTHER
Intervention: galyfilcon A
Description: contact lenses worn bilaterally for 8-12 hours

Intervention type: DEVICE
Group type: OTHER
Intervention: galyfilcon A
Description: contact lenses worn bilaterally for 8-12 hours
Study: NCT04226430

Intervention type: DEVICE
Intervention: Cytokine aphaeresis
Description: The Cytosorb cartridge was either used alone in hemoperfusion mode or, if renal replacement therapy was clinically indicated, inserted proximally into a conventional continuous veno-venous hemofiltration (CVVH) or continuous veno-venous hemodiafiltration (CVVHDF) circuit. Before the start of the Cytosorb therapy, adequate anti-coagulation was confirmed when target partial thromboplastin time (PTT) of 60±80 seconds, or an activated clotting time (ACT) of 180±210 seconds was achieved with systemic heparin. Antibiotics were administered after each Cytosorb therapy whenever possible.

Intervention type: DEVICE
Intervention: Cytokine aphaeresis
Description: The Cytosorb cartridge was either used alone in hemoperfusion mode or, if renal replacement therapy was clinically indicated, inserted proximally into a conventional continuous veno-venous hemofiltration (CVVH) or continuous veno-venous hemodiafiltration (CVVHDF) circuit. Before the start of the Cytosorb therapy, adequate anti-coagulation was confirmed when target partial thromboplastin time (PTT) of 60±80 seconds, or an activated clotting time (ACT) of 180±210 seconds was achieved with systemic heparin. Antibiotics were administered after each Cytosorb therapy whenever possible.
Study: NCT02647112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bladder EpiCheck
Description: Urine test for the monitoring of bladder cancer recurrence
Study: NCT01512225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone maleate
Description: domperidone maleate tablet 10 mg orally three times daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: placebo tablet 10 mg orally three times daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Domperidone maleate
Description: domperidone maleate tablet 10 mg orally three times daily for 14 days
Study: NCT03326687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment ABAB
Description: Participants will perform the phases in the ABAB order.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment BABA
Description: Participants will perform the phases in the BABA order.
Study: NCT04079868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bone Health Service Model
Description: Patients in PACTs randomized to the BHS model will have osteoporosis screening, education, and follow-up handled centrally by the bone health team.
Study: NCT00628732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and Topotecan
Description: Two courses of cyclophosphamide at 50 mg/m2/dose and topotecan 0.8 mg/m2/dose by mouth every morning for 14 days each.
Study: NCT03496038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L-PRF
Description: The use of the L-PRF as graft material for sinus augmentation procedure will be analysed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DBBM
Description: The use of bovine xenograft as graft material for sinus augmentation procedure will be analysed
Study: NCT01482819

Intervention type: DEVICE
Group type: OTHER
Intervention: polymacon
Description: contact lenses worn bilaterally for 8-12 hours

Intervention type: DEVICE
Group type: OTHER
Intervention: polymacon
Description: contact lenses worn bilaterally for 8-12 hours

Intervention type: DEVICE
Group type: OTHER
Intervention: polymacon
Description: contact lenses worn bilaterally for 8-12 hours

Intervention type: DEVICE
Group type: OTHER
Intervention: polymacon
Description: contact lenses worn bilaterally for 8-12 hours
Study: NCT01810926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Thiotepa
Description: iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Cyclosporine A
Description: iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Cyclosporine A
Description: iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Methotrexate
Description: iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Methotrexate
Description: iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11
Study: NCT00626483

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RNA-loaded dendritic cell vaccine
Description: Only one dose of DCs (2 x 10\^7) is being assessed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basiliximab
Description: Basiliximab 20 mg and 40 mg is being assessed depending on dose-cohort enrollment.
Study: NCT00211783

Intervention type: PROCEDURE
Intervention: fMRI
Description: there is no intervention
Study: NCT02373384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral alkalinization (Potassium citrate, Allopurinol)
Description: Eligible patients, who fulfilled the study criteria, will be instructed For; Oral alkalinization therapy~* Potassium citrate 20 mEq three times daily~* Hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will receive:~Allopurinol, a competitive inhibitor of xanthine oxidase, in a dose of 300 mg daily.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life style modification
Description: Eligible patients, who fulfilled the study criteria, will be also instructed for;~Adequate fluid intake in order to maintain urine volume between 2-3 L per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary recommendations (decrease purine rich diet as red meat and fish, increase vegetables)
Description: Eligible patients, who fulfilled the study criteria and they are hyperuricosuric (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will be also instructed for; Dietary modification will be advised in the form of decrease purine rich diet as red meat and fish, increase vegetables.
Study: NCT04788589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedation and ventilator weaning protocol
Description: Subjects randomized to this group will underwent sedation and ventilator weaning protocol as mentioned before.